|

Dabrafenib Clinical Trials

14 actively recruiting trials across 5 locations

▲ +1 trial since May 2026

Also known as: BRAF Inhibitor GSK2118436, DRB436, GSK-2118436, GSK-2118436A, GSK2118436 +2 more

Pipeline

Phase 1: 2Phase 2: 8Phase 3: 1Phase 4: 2

Top Sponsors

  • Novartis Pharmaceuticals2
  • Tianjin Medical University Second Hospital1
  • Tianjin Medical University Cancer Institute and Hospital1
  • The Netherlands Cancer Institute1
  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1

Indications

  • Cancer14
  • Solid Tumor3
  • Lung Cancer3
  • Cerebellar Liponeurocytoma1
  • Extraventricular Neurocytoma1

Other9 trials

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Phase 2
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Melanoma Metastasized to the Brain and Steroids
Phase 2
Precision Cancer Therapy in Rare Cancers
Phase 2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Anchorage, Alaska1 trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Anchorage Associates in Radiation Medicine

Phase 3

Phoenix, Arizona1 trial

Pediatric Long-Term Follow-up and Rollover Study

Phoenix Children s Hospital

Phase 4

Scottsdale, Arizona1 trial

Dabrafenib and/or Trametinib Rollover Study

Honor Health Research Institute

Phase 4

Duarte, California1 trial

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1

Iowa City, Iowa1 trial

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Iowa

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.